Clinical Trials Directory

Trials / Terminated

TerminatedNCT06098248

Evaluation of cCeLL-Ex Vivo Confocal Microscopy for Real-time Brain Tumor Diagnosis

A Prospective, Multi-centered, Assessor-blinded Clinical Performance Study to Evaluate the Sensitivity and Specificity of the cCeLL-Ex Vivo Device for Intraoperative Brain Tumor Diagnosis.

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
285 (actual)
Sponsor
VPIX Medical · Industry
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

Intra-operative evaluation of residual brain tumor currently relies on frozen-section histopathology, which typically requires 20-30 minutes for tissue processing and interpretation, prolonging operative time and increasing staffing demands. Confocal Laser Fluorescence Microscopy (cCeLL - Ex vivo) acquires real-time, high-resolution fluorescence images of resected tissue and therefore may serve as a rapid alternative or adjunct to frozen sections. This prospective, multi-center study was designed to systematically assess the clinical performance of cCeLL - Ex vivo during brain-tumor surgery.

Detailed description

Primary Objective Demonstrate non-inferiority of cCeLL - Ex vivo versus frozen-section histopathology in terms of clinical sensitivity and specificity for intra-operative brain-tumor diagnosis. Secondary Objectives Compare diagnostic turnaround time between cCeLL - Ex vivo and frozen section. Evaluate tumor-type classification accuracy for each modality. Determine the average number of images required for definitive cCeLL - Ex vivo interpretation. Quantify overall diagnostic performance of cCeLL - Ex vivo using the area under the ROC curve (AUC).

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTcCeLL - Ex vivoNeoplastic brain tissue biopsied from participant will be visualized, and images will be captured using cCeLL - Ex vivo.

Timeline

Start date
2023-01-01
Primary completion
2024-11-27
Completion
2024-11-27
First posted
2023-10-24
Last updated
2025-12-15
Results posted
2025-12-15

Locations

4 sites across 2 countries: Canada, South Korea

Source: ClinicalTrials.gov record NCT06098248. Inclusion in this directory is not an endorsement.